COVID-19 vaccine

World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) ¹’² has also completed its review of the vaccine and recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks.
Vaccine efficacy for symptomatic and hospitalized disease was estimated to be 79%, all age groups combined.

Once vaccinated with Sinopharm Covid-19 vaccine, the immune system can respond to an infection of live coronaviruses. B cells produce antibodies that stick to the invaders. Antibodies that target the spike protein can prevent the virus from entering cells¹.

Sinopharm’s clinical trials have demonstrated that Covid-19 vaccine can protect people against Covid-19. But no one can yet say how long that protection lasts. It’s possible that the level of antibodies drops over the course of months. But the immune system also contains special cells called memory B cells that might retain information about the coronavirus for years or even decades. As with all vaccinations under the EUL, Sinopharm will continue to submit ongoing data for the continued safety and quality of the vaccine.

According to the WHO ¹’², a large, multi-country phase three trial showed after administering two doses at an interval of 21 days, the Sinopharm Covid-19 vaccine is 79% effective against symptomatic SARS-CoV-2 infection two weeks after the second dose. It was also reported to be 79% effective against hospitalisation.

Sinopharm Covid-19 vaccine is not recommended for individuals with a history of anaphylaxis to any component of the Sinopharm Covid-19 vaccine or have body temperature over 38.5ºC should postpone vaccination until they no longer have a fever. Special population group of such as individuals with comorbidities, children and pregnant woman should check with their healthcare physician and refer to current country’s recommended vaccination criteria to determine if suitable for Sinopharm Covid-19 Vaccine.

世卫组织（WHO ¹’² ）建议第一剂和第二剂之间间隔3-4周。建议所有接种疫苗的人接种两剂。与此同时，在各国进行的临床试验中仍在评估额外剂量的必需性和接种时间。

参考文献
1. The Sinopharm COVID-19 vaccine: What you need to know (2021, May 7). Retrieved July 27 2021 https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
2. Wilder-Smith, A., Hombach, J., Marti, M., & O’Brien, K. (2021, May 24). Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm. Retrieved July 27, 2021, from World Health Organisation website: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BIBP-2021.1
3. COVID-19 advice for the public: Getting vaccinated (2021, July). Retrieved July 28 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice

Disclaimer:

本网站所包含的信息包括但不限于文本、图形、图像和其他材料，仅用于教育目的，基于公开信息，并根据 Medic Surgical & Laser Clinic 的现有知识而准备。本网站上的任何材料均不得取代专业的医疗建议。如果您有任何与医疗状况有关的问题，或者您是否有资格接种上述疫苗，请始终寻求您的医生或其他合格医疗保健专业人员的建议。

Medic Surgical & Laser Clinic 致力于保护您的隐私。我们严格保密您提供的所有个人数据，并且只会以向您提供健康相关新闻更新和服务更新（包括但不限于 Covid-19 疫苗）的方式使用您的个人数据。所有对“Medic Surgical & Laser Clinic”、“我们”、“我们的”和“我们的”的提及统称为 Medic Surgical & Laser Clinic 及其所有联营公司，以及母控股公司 Clearbridge Medical Group。

Medic Surgical & Laser Clinic is committed to safeguarding your privacy. We treat all personal data provided by you in strict confidence, and will only use your personal data in the manner of providing you updates of health-related news and updates of services including and not limited to Covid-19 Vaccine. All references to the “Medic Surgical & Laser Clinic”, “we”, “us” and “our” refer collectively to the Medic Surgical & Laser Clinic, and all its associates, and Clearbridge Medical Group, the parent holding company.